Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.

Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical manufacturers can honor the 340B price. This program represents an ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...